CHENGDU, China, Jan. 2, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates regarding the Alliance discussions with industrial leaders (private and state-owned enterprises) in China's pharmaceutical market to form integrated platform of its mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL).


    1. The Alliance platform is to be established based upon TPI's newly
       completed and imminently GMP-certified Qionglai Facility (QLF).
    2. The Alliance is to focus on TPI's core product portfolio along with other
       portfolio drugs with the possibility of integrating additional products
       beyond the current indication categories of cardiovascular, viral
       infection and immunology.
    3. The Alliance is to be established with TPI's wholly owned subsidiary
       Chengdu Tianyin Pharmaceutical owning majority stake of the Alliance with
       the strategic partner owning a minority stake with the total registered
       capital for the Alliance in the range of RMB 200 million - RMB 250
       million, approximately $30 million - $40 million.
    4. The Alliance is to integrate the current TPI's sales force with the
       network resources brought by the industrial partner to achieve
       significant improvement on the revenue of TPI's core portfolio with the
       focus on GMOL.
    5. TPI's Jiangchuan macrolide facility (JCM), a wholly owned subsidiary of
       Chengdu Tianyin, currently valued at $18 million, is not included in the
       Alliance due to the nature of JCM's business specializing on API
       manufacturing and sales.

"In recent years, TPI has met challenges due to intensified market competition and policy changes amid the ongoing healthcare reform in China. In an effort to regain the momentum of revenue growth, we ally with well-entrenched industrial leaders to synergize and optimize various resources to improve the depth and coverage of sales networks." TPI's Chairman and CEO, Jiang, Guoqing commented, "We will provide updates when these efforts substantiate."

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. For more information about TPI, please visit: http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel: +86-28-8551-6696 (Chengdu, China)
Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tpi-updates-on-alliance-discussion-300015072.html

SOURCE Tianyin Pharmaceutical Co., Inc.